eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2018
vol. 14
 
Share:
Share:
more
 
 
Clinical research

Impact of lenalidomide exposure on blood cell collection for autotransplants in persons with POEMS syndrome

Hao Cai, Jiefei Bai, Jian Li, Huacong Cai, Minghui Duan, Xinxin Cao, Miao Chen, Daobin Zhou, Wei Zhang

Arch Med Sci 2018; 14, 5: 1048–1054
Online publish date: 2016/11/02
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

POEMS syndrome is a rare plasma cell disorder, characterized by peripheral polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes. Associations with Castleman disease and osteopetrosis are also reported [1]. Although the etiology and pathogenesis of POEMS syndrome are unclear, vascular endothelial growth factor (VEGF) may be important [2]. There is no standard treatment for POEMS syndrome. High-dose melphalan followed by an autologous hematopoietic cell transplant is effective [3–5], but it is sometimes difficult to obtain sufficient numbers of blood cells to perform an autotransplant [6].
Recently, lenalidomide was reported to be active in POEMS syndrome [7–10]. However, there is concern that lenalidomide therapy might worsen the problem of collecting adequate numbers of blood cells for a subsequent autotransplant [11–15]. For example, in persons with plasma cell myeloma, lenalidomide therapy is associated with less efficient blood cell collection of mobilization with granulocyte-colony stimulating factor (G-CSF) [11]. There are few data on the impact of lenalidomide therapy on blood cell mobilization and collection in persons with POEMS syndrome. We sought to answer this question by collecting blood cells from 43 subjects with POEMS treated or not treated with lenalidomide.

Material and methods

Subjects

We retrospectively report 43 consecutive subjects with POEMS syndrome seen at Peking Union Medical College Hospital between March, 2013 and March, 2014. Nineteen received 1–4 cycles of lenalidomide and dexamethasone. Twenty-four others received no therapy before apheresis. Both cohorts then received cyclophosphamide and G-CSF followed by apheresis to collect blood CD34+ cells. Subjects met diagnostic criteria for POEMS syndrome [16] including major (polyneuropathy and monoclonal plasma proliferative disorder) and ≥ 1 minor criterion (bone lesions, Castleman disease, organomegaly, edema, endocrinopathy, skin changes and papilledema). The study was approved by the Institutional Review Board of Peking Union Medical College Hospital, and all subjects gave written informed consent.

Lenalidomide cohort

Subjects received 4 cycles of lenalidomide, 3 subjects received 3, 1 subject received 2, 10 mg/day orally, on days 1–21 and dexamethasone, 40 mg/day orally on days 1, 8, 15 and 22 of each 28 day therapy cycle. The total dosages of lenalidomide or dexamethasone for each subjects see Supplemental Table.

Mobilization

Cyclophosphamide, 2 g/m2, given on day 0 followed by G-CSF, 300 µg bid subcutaneously, on day 8, was used to mobilize CD34+ cells into the blood on day 11 or 12 after cyclophosphamide subjects underwent apheresis using a Haemonetics multi-component collection system cell separator (Haemonetics Corporation, Braintree, MA). Subjects were evaluated for vascular access before apheresis to determine the best route of venous access. Blood was processed three times during each collection using citrate dextrose solution as an anticoagulant. Total nucleated cell numbers and CD34+ frequency were assayed. Blood CD34+ cells were first assayed on day 10 or 11 corresponding to 4 days after giving G-CSF. We then assayed CD34 cells daily until the apheresis procedure was completed. Bone marrow CD34 was first assayed the day before giving cyclophosphamide and then 9 to 10 days later, corresponding to 3 days after giving G-CSF. Subjects were termed poor mobilizers if < 1–2 × 106/kg CD34+ cells were collected from 1 mobilization procedure. Subjects who had < 1 × 106/kg CD34+ cells collected or had no collection were termed very poor mobilizers.
Collections were typically successful in ≤ 3 days in subjects with blood CD34+ level > 6 × 106 cells/l. We also performed bone marrow puncture to obtain the sample to analyze CXCR4 expression (Figure 1).

Flow cytometry

Before and after mobilization and apheresis, bone marrow cells were collected from 7 recipients of lenalidomide and dexamethasone and 9 subjects with no prior therapy. The number of CD34+ cells and CXCR4 expression on CD34+ cells were measured, and the frequency of blood CD34+ cells was determined by flow cytometry (BD FACSCalibur, USA). CD34+ cells were gated using the ISHAGE method. Specimens were analyzed using an internal control (IgG1a PE, IgG2k PE-CY7) and double test. Antibodies included: CXCR4 PE-CY7 Mouse Anti-Human Cat: 560669 BD, USA; Mouse IgG2a K, Isotype PE-CY7 Cat: 557907 BD, USA; CD45 PerCP Cat: 347464 BD, USA; IgG11 PE Cat: 348057 BD, USA; CD34 8G12 PE Cat: 348057 BD, USA; BD FACS Lysing solution Cat: 349202 BD, USA. All antibodies were used according to the manufacturer’s recommendations (fluorescent-labeled antibody was purchased from BD, USA). CXCR4 expression on CD34+ cells was expressed as mean fluorescent intensity (MFI) on cells from bone marrow samples.

Statistical analysis

Student’s t-test or Mann-Whitney U test was used to compare continuous group variables. A 2 test was applied for categorical data. Statistical tests used two-sided tests. Means and standard deviations were obtained with IBM SPSS Statistics Version 19.0 software (SPSS Inc, Chicago, IL). P-values < 0.05 were considered significant.

Results

Subjects

Forty-three consecutive subjects with POEMS syndrome were studied. Pre-apheresis variables are summarized in Table I. The schema describing patient treatment can be found in Figure 2. Mobilization and apheresis Twenty-nine subjects were termed good mobilizers (CD34+ cells ≥ 2 × 106/kg) including 12 subjects in the lenalidomide cohort and 17 in the control cohort. Eight subjects were termed poor mobilizers (CD34+ cells 1–2 × 106/kg) including 4 subjects in each cohort. Six subjects were termed very poor mobilizers including 3 in each cohort. There was no significant difference in the distribution of types of mobilizers in the 2 cohorts (Table II).
Four subjects, 2 in each cohort, had no apheresis because of a low frequency of blood CD34+ cells (< 5 × 106/l) after cyclophosphamide and G-CSF. Thirty-nine subjects had apheresis. Lenalidomide-treated subjects and controls had similar frequencies of blood CD34+ cells (0.25%, 95% CI: 0.03–1.39% vs. 0.32%, 0.04–1.47%; p = 0.472) and numbers of blood CD34+ cells (10, 5–77 × 106/l vs. 14, 95% CI: 6–101 × 106/l; p = 0.312). In lenalidomide-treated subjects, the number of CD34+ cells collected was 2.32 (95% CI: 0.6–6.8 × 106/kg), compared with 2.8 (1.0–9 × 106/kg) in controls (p = 0.521; Table II).
Table III shows the frequency of CD34+ cells and CXCR4 expression on bone marrow CD34+ cells before and after mobilization. Before mobilization bone marrow CD34+ frequency in both cohorts was similar (0.93%, 0.38–2.04% vs. 1.1%, 0.28–2.02%; p = NS). After mobilization, frequency of CD34+ increased (Figure 3 A) in both cohorts (1.21%, 0.35–5.03%) in lenalidomide-treated subjects vs. 1.74% (0.94–3.47%) in controls (p = 0.828). After mobilization, mean fluorescent intensity of CXCR4 expression on CD34+ cells in controls decreased from 58 ±43 to 31 ±40, whereas in subjects receiving lenalidomide CXCR4 expression increased from 55 ±34 to 89 ±16 (Figure 3 B; p = 0.017; Table III).

Safety

Three controls had fever and neutropenia after mobilization, 4 had severe edema, and 3 developed acute renal failure. Two lenalidomide-treated subjects had fever and neutropenia and 1 had severe edema.

Discussion

Autotransplants are recognized as safe and effective therapy of POEMS syndrome [17]. We reported inability to collect sufficient numbers of CD34+ cells for an autotransplant in about one-half of subjects with newly diagnosed POEMS syndrome in 2013 [6]. Disease was correlated with poor mobilization. Recently, therapy with lenalidomide and dexamethasone was reported to be effective in POEMS syndrome [9, 10]. However, some data suggest that extensive lenalidomide therapy decreases the likelihood of collecting sufficient numbers of CD34+ cells for an autotransplant [11, 12]. We analyzed data from 43 subjects with POEMS syndrome undergoing mobilization and apheresis, about one-half of whom received ≤ 4 cycles of lenalidomide and dexamethasone. We found no difference in the efficiency of mobilization and CD34+ cell collection compared with untreated controls. Interestingly, although CXCR4 expression on bone marrow CD34+ cells from lenalidomide-treated subjects was increased, there was no impact on mobilization efficiency. There was also no increase in mobilization and apheresis in subjects receiving lenalidomide compared with controls. LD treatment eliminated the inhibitory effect of adhesion factors after classic mobilization, and CXCR4 expression increased. In an in vitro study of lenalidomide on stem cell mobilization, Li et al. reported that lenalidomide did not damage bone marrow CD34+ hematopoietic stem cells, but significantly increased CXCR4 expression in CD34+ cells. Also, SDF-1 mRNA did not increase [15]. So, lenalidomide did not induce bone marrow mesenchymal cell secretion of SDF-1. Increased expression of CXCR4 after lenalidomide therapy may result from enhanced transportation of intracellular CXCR4 to the cell membrane with reduced internalization [15].
Mazumder et al. reported the impact of more than four cycles of lenalidomide on peripheral blood stem cell (PBSC) mobilization in multiple myeloma patients (70% failed) [11]. But four or less cycles remained reliable (23% failed) [10]. Like what we found in POEMS patients, less than 5 cycles of lenalidomide did not have an impact on mobilization efficiency, but also improved mobilization safety after treatment. There are several limitations to our study. Subjects were assigned, not randomized to receive lenalidomide and dexamethasone vs. no therapy. Also, numbers of cycles of lenalidomide and dexamethasone were not prospectively specified. Nevertheless, we found no adverse impact of therapy with lenalidomide and dexamethasone on efficacy of CD34+ cell collection after mobilization. Our results should be validated in a randomized study.
Ghosh et al. reported that the influence of dexamethasone on the cell surface of CXCR4 can only last a few minutes [18]. So we can ignore the role of dexamethasone’s effect on hematopoietic cell mobilization.

Acknowledgments

Hao Cai and Jiefei Bai contributed equally to this work.
Wang Xuan, Lian-Feng Chen and Jing-Chao Liu provided technical assistance. Professor Robert Peter Gale (Imperial College London) kindly reviewed and edited the typescript.

Conflict of interest

The authors declare no conflict of interest.

References

1. Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21: 285-99.
2. D’Souza A, Hayman SR, Buadi F, et al. Utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 2011; 118: 4663-5.
3. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004; 104: 3400-7.
4. Nakaseko C. Autologous stem cell transplantation for POEMS syndrome. Clin Lymphoma Myeloma Leuk 2014; 14: 21-3.
5. Xiong T, Chen X, Wei H, et al. Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells. Arch Med Sci 2015; 11: 301-6.
6. Li J, Zhang W, Duan MH, et al. PBSC mobilization in newly diagnosed patients with POEMS syndrome: outcomes and prognostic factors. Bone Marrow Transplantation 2013; 48: 233-7.
7. Lestang E, Caristan A, Neel A, et al. Lenalidomide as frontline therapy in POEMS syndrome: a retrospective case series of 8 patients. Leuk Lymphoma 2015; 56: 1895-6.
8. Semeraro M, Vacchelli E, Eggermont A, et al. Trial Watch: lenalidomide based immunochemotherapy. Oncoimmunology 2013; 2: e26494.
9. Royer B, Merlusca L, Abraham J,  et al. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 2013; 88: 207-12.
10. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012; 2012: 513702.
11. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280-1.
12. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-42.
13. Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010; 115: 605-14.
14. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005; 105: 3833-40.
15. Li S, Fu J, Ma H, Mapara MY, Lentzsch S. Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. Leukemia 2013; 27: 1407-11.
16. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101: 2496-506.
17. Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 214-23.
18. Ghosh MC, Baatar D, Collins G, et al. Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck. Blood 2009; 113: 575-84.
Copyright: © 2016 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe